OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.
Antimicrobial stewardship programs are important in reducing the reliance on antibiotic use to drive down the rates of clostridioides difficile infection (CDI) in hospitals.
It has long been known that antibiotic use is a major risk factor of these types of hospital-acquired infections, but how to avoid the use is a tougher challenge.
In an interview with HCPLive®, Paul Feuerstadt , MD, Yale University School of Medicine, explained the value of stewardship programs and how they will result in future reductions of hospital-acquired C difficile infections.
Feuerstadt presented data during the recent 2021 American College of Gastroenterology (ACG) Annual Meeting about RBX2660, a potential microbial treatment for the infection.
He also spoke about how the COVID-19 pandemic has impacted C difficile cases.
There have been several reports and studies highlighting a reduction in cases due to all the mitigation measures put in place, including social distancing, a reduction in visitors, and enhanced sanitation measures.
However, Feuerstadt said rates likely stayed relatively stable throughout the pandemic, mainly due to an increased use of antibiotics.
But he did say once the threat of COVID-19 finally subsides there might still be a drastic reduction as hospitals will likely maintain many of the measures that have been put in place.